Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
706 results about "Complex dyslipidemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood.
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:DASSEUX JEAN LOUIS +5
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:JEAN LOUIS DASSEUX +5
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
InactiveUS20060211762A1Effective treatmentBiocideMetabolism disorderDyslipidemiaCoronary artery disease
A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.
Owner:RELIANT PHARMACEUTICALS INC +1
Omega-3 Fatty Acids and Dyslipidemic Agent for Lipid Therapy
InactiveUS20090012167A1Effective treatmentBiocideAnimal repellantsDyslipidemiaCoronary artery disease
Owner:RELIANT PHARMACEUTICALS INC +1
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
InactiveUS20080125490A1Effective pharmaceutical treatmentMinimize side effectsBiocideAnimal repellantsDyslipidemiaCoronary event
Compositions comprising omega-3 fatty acids are provided, where the compositions are useful for treating cardiovascular disease in patients suffering from chronic kidney disease (CKD), preventing its further progression, and treating underlying risk factors such as hypertension, dyslipidemia, obesity and / or diabetes. Also provided are methods of using the compositions to reduce the occurrence of or prevent major coronary events, including myocardial infarctions, in patients with CKD.
Owner:PRONOVA BIOCARE AS
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
InactiveUS20080306154A1Effective treatmentReduce generationBiocideMetabolism disorderDyslipidemiaCoronary event
Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and / or diabetes.
Owner:PRONOVA BIOCARE AS
Compositions and methods for silencing apolipoprotein c-iii expression
ActiveUS20120184595A1Reduce hyperlipidemiaSlow onsetOrganic active ingredientsPowder deliveryDyslipidemiaLipid formation
The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
Owner:PROTIVA BIOTHERAPEUTICS
Antidiabetic bicyclic compounds
ActiveUS20070265332A1Useful in treatmentBiocideSenses disorderHypertriglyceridemiaG protein-coupled receptor
Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Owner:MERCK SHARP & DOHME LLC
Statin and omega-3 fatty acids for reduction of apo-b levels
InactiveUS20080085911A1Reduce additionalAvoid loweringBiocideMetabolism disorderDyslipidemiaApolipoproteins E
Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
Owner:RELIANT PHARMACEUTICALS INC
Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof
InactiveUS20060211749A1Reduced dosages of PPAR agonistEffective treatmentBiocideMetabolism disorderDyslipidemiaFasting glucose
A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and / or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and / or the reduction of incidence and / or the delay of onset of diabetes.
Owner:RELIANT PHARMACEUTICALS INC
Gip analog and hybrid polypeptides with selectable properties
ActiveUS20080312157A1Increased insulin secretionDecreasing bone loss bonePeptide/protein ingredientsMetabolism disorderDyslipidemiaFeeding disability
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP
Hybrid polypeptides with selectable properties
InactiveUS20060094652A1Reverse glucose intoleranceIncrease beta cell massPeptide/protein ingredientsAntibody mimetics/scaffoldsDyslipidemiaBlood plasma
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:AMYLIN PHARMA INC
Ether compounds
InactiveUS6459003B1Reduce contentLower cholesterol levelsNervous disorderAntipyreticDyslipidemiaCholesterol
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Mao-b inhibitors useful for treating obesity
InactiveUS20070078172A1Reduce the amount requiredEfficient reductionBiocideAnimal repellantsDyslipidemiaBlood lipids
The invention provides a method of treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.
Owner:JENRIN DISCOVERY
Tetrahydrocarbazoles and derivatives
The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and / or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and / or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis / fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired / improvable cognitive function.
Owner:F HOFFMANN LA ROCHE & CO AG
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:DASSEUX JEAN LOUIS +4
ABCA-1 elevating compounds and methods
Disclosed are novel compounds of Formula Iuseful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the plasma of a mammal, in particular humans.
Owner:CV THERAPEUTICS INC
Ketone compounds and compositions for cholesterol management and related uses
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
InactiveUS6518412B1Improve the level ofIncrease productivityAntibacterial agentsBacteriaDyslipidemiaAmphipathic helix
The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
Owner:DASSEUX JEAN LOUIS +5
Apolipoprotein A-I agonist compounds
Owner:DASSEUX JEAN LOUIS +5
Combination therapy for the treatment of dyslipidemia
InactiveUS20060148721A1Effective treatmentHigh levelBiocideOrganic chemistryDyslipidemiaBlood lipids
The present invention relates to compositions comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
Owner:MERCK SHARP & DOHME CORP
Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes
InactiveUS20070203521A1Ameliorate or eliminate an attendant conditionElectrotherapyDyslipidemiaAcute hyperglycaemia
A tissue modulation device, for treating at least one of obesity, metabolic syndrome, and Type 2 diabetes in a patient, is described. In some embodiments, the device includes a storage module having computer-readable instructions for delivering an electrical stimulation pattern to a splanchnic nerve of the patient. The stimulation pattern includes at least one on-time. The on-time includes at least one of a suprathreshold period and a subthreshold period. The splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve. The pattern is effective to ameliorate at least one attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition includes dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and / or insulin resistance.
Owner:ADVANCED NEUROMODULATION SYST INC
Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
Owner:MERCK SHARP & DOHME LLC
Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
InactiveUS20050171204A1To promote metabolismImprove propertiesBiocideSenses disorderDyslipidemiaEnantiomer
The present invention provides the S enantiomer of a compound of formula (I) wherein n is 1 or 2 as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Owner:ASTRAZENECA AB
Compounds that modulate PPAR activity and methods for their preparation
InactiveUS6875780B2BiocideOxygen-containing compound preparationAcute hyperglycaemiaHypertriglyceridemia
This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
Owner:WARNER-LAMBERT CO
Ether compounds and compositions for cholesterol management and related uses
InactiveUS6713507B2Reduce contentLower cholesterol levelsAntibacterial agentsBiocideDyslipidemiaPeroxisome proliferator-activated receptor
Owner:ESPERION THERAPEUTICS
GIP analog and hybrid polypeptides with selectable properties
Owner:ASTRAZENECA PHARMA LP
Glucagon antagonists/inverse agonists
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and / or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
Owner:PFIZER INC
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
InactiveUS7501405B2Reduce development riskBiocideMetabolism disorderHypertension medicationsDyslipidemia
Owner:VTV THERAPEUTICS LLC
Methods for treating metabolic disorders using fgf
InactiveUS20130116171A1High in fatOrganic active ingredientsPeptide/protein ingredientsDyslipidemiaFatty liver
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
Owner:SALK INST FOR BIOLOGICAL STUDIES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com